Positron relocates HQ to Indiana

Positron, a nuclear cardiology company, has executed a memorandum of understanding (MOU) with the City of Noblesville, Ind., to relocate its corporate headquarters, research & development and product manufacturing facilities to Noblesville.

Included in the MOU are economic incentives for the development of the company’s 70 MeV cyclotron project and radiopharmaceutical manufacturing facility also to be located in Noblesville.

Positron is proposing to make a capital investment of approximately $55 million dollars for this project in conjunction with economic development incentives from Noblesville and the state of Indiana, as well as various other project financing opportunities.

This cyclotron, once completed, will be a commercial cyclotron for isotope production within the U.S. and will advance Positron’s objectives for the production of medical isotopes and radiopharmaceuticals used in cardiac PET imaging and diagnostic and therapeutic medical radiopharmaceuticals, according to the company.

Positron said its development plans are expected to create more than 80 jobs in Noblesville over the next three to five years.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.